Castle Biosciences gets $11.7M Series F for cancer diagnostics
In order to fuel sales of its cancer diagnostics, Texas startup Castle Biosciences just raised the first, $11.7 million tranche of a $20 million Series D.
Castle Biosciences commercializing tests for orphan cancers, raising $11.8M
Texas cancer diagnostics company Castle Biosciences plans to expand the clinical availability of its tests that assess “rare and underserved cancers,” particularly one for cutaneous melanoma. It has wrapped up an $11.8 million round to do so, the company said. The round was led by new investor HealthQuest Capital; existing investors Mountain Group Capital and Affiliates, Longfellow […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.